Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Inclusion Criteria: * Patients must have a Karnofsky performance status of \>= 60 * Patients must have a life expectancy \> 8 weeks * All patients must sign an informed consent document indicating that they are aware of the investigational nature of this study * Patients must sign an authorization for the release of their protected health information * Patients must have a magnetic resonance imaging (MRI) scan performed within 14 days prior to initial protocol treatment * Patients must be registered in the University of California at San Francisco (UCSF) Neuro-Oncology database prior to treatment with study drug * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L * Platelets \>= 100 x 10\^9/L * Hemoglobin (Hb) \> 9 g/dL * Serum bilirubin =\< 1.5 x upper limit of normal (ULN) * International normalized ratio (INR) \< 1.5 (anticoagulation is allowed if target INR =\< 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight \[LMW\] heparin for \> 2 weeks at the time of registration) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN * Serum creatinine =\< 1.5 x ULN * Fasting serum cholesterol =\< 300 mg/dL OR =\< 7.75 mmol/L AND fasting triglycerides =\< 2.5 x ULN; NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication * Patients must have histologically proven intracranial low-grade glioma at initial diagnosis; low-grade gliomas i…